<DOC>
	<DOCNO>NCT01460511</DOCNO>
	<brief_summary>This multi-center , randomize , double-blinded , placebo-controlled , parallel , 4-week study 60 pediatric patient ( 4-11 year old ) asthma , compare E004 Placebo HFA-MDI pediatric patient 4-11 year age asthma .</brief_summary>
	<brief_title>Evaluation Efficacy Safety E004 Children With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Generally healthy male , premenarchal female , child age 4 11 year upon Screening . With documented asthma , require inhale epinephrine beta2agonist treatment , without concurrent antiinflammatory therapy least 6months prior Screening . Being capable perform spirometry FEV1 Satisfying criterion asthma Can tolerate withholding treatment inhale bronchodilator allow medication minimum washout period Demonstrating Screening Baseline FEV1 50 90 % Polgar predict normal value . Demonstrating Airway Reversibility , Demonstrating satisfactory technique use metereddose inhaler ( MDIs ) hand hold peak expiratory flow meter , training . Has properly consent participate study . Any current past medical condition , per investigator discretion , might significantly affect pharmacodynamic response study drug Concurrent clinically significant cardiovascular , hematological , renal , neurologic , hepatic , endocrine , psychiatric , malignant disease . Known intolerance hypersensitivity component study drug Recent infection respiratory tract Use prohibit medication Having investigational drug/device study last 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Mild bronchial asthma</keyword>
</DOC>